Author

Jeanenne Chung

Institution: Takeda Oncology (United States)

Observed institution: Takeda Oncology (United States)

OpenAlex ID: A5034336285

Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).

2013 · Anas Younes, John Radford, et al. · Journal of Clinical Oncology · 2

Works count: 1

Citation count: 2

H-index: 1

I10-index: